Enhertu OK ends 10-year EU gap in frontline breast cancer
Enhertu plus Perjeta has become the first new frontline therapy approved for advanced HER2-positive breast cancer in the EU for over a decade.
Roche taps Simcere for autoimmune trispecific for $1.53bn
Roche is paying $75m upfront for a trispecific drug developed by China's Simcere Zaiming for B-cell-mediated autoimmune disorders and blood cancers.
Novartis sets sights on new oral MS drug after phase 3 wins
Novartis' oral BTK inhibitor remibrutinib has shown efficacy in a pair of phase 3 trials in multiple sclerosis, boosting its blockbuster credentials.
GSK pushes 'next-generation' mRNA flu shot into phase 3
Buoyed by positive data in a phase 2 trial, GSK will start a phase 3 programme for an mRNA-based flu shot targeting both HA and NA flu antigens.
Novartis halts CAR-T trials after patient deaths
Novartis stops eight trials of CAR-T rap-cel in autoimmune diseases after three deaths, with BMS also halting studies of zola-cel as a precaution.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
World Novel Drug Discovery Summit South Korea
Korea’s First Industry Forum Driving Best-in-Class Discovery for Next-Generation Modalities
2nd World-RNA Based Therapeutics & Vaccines Summit South Kor...
Korea’s Forum to Advance mRNA, CircRNA & saRNA Medicines for Clinical & Commercial Readiness
AI, Forecasting, Insights and Analytics for Smarter Decision...
Learn from case studies, expert-led panels, roundtable discussions, and interactive workshops on Gen AI-powered forecasting
30th Portfolio Decision-Making & Prioritisation for Pharma
Pharmaceutical portfolio decision-making is facing structural pressure.
R&D Governance, Controlling and Innovation for Pharma
The Marcus Evans R&D Governance, Controlling, and Innovation for Pharma conference will take place at the Crowne Plaza - Frankfurt Congress Hotel